U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer Posted on February 28, 2022 By U.S. FDA Accepts for Priority Review BMS’s Application for Opdivo Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer News
